Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Gross Profit (2017 - 2026)

Lexaria Bioscience's Gross Profit history spans 10 years, with the latest figure at $20000.0 for Q1 2026.

  • Quarterly results put Gross Profit at $20000.0 for Q1 2026, down 88.51% from a year ago — trailing twelve months through Feb 2026 was $368000.0 (down 29.66% YoY), and the annual figure for FY2025 was $703203.0, up 53.05%.
  • Gross Profit for Q1 2026 was $20000.0 at Lexaria Bioscience, down from $174000.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $181203.0 in Q4 2024 to a low of $20000.0 in Q1 2026.
  • The 5-year median for Gross Profit is $84000.0 (2024), against an average of $103125.1.
  • The sharpest move saw Gross Profit soared 886.04% in 2022, then plummeted 88.51% in 2026.
  • Year by year, Gross Profit stood at $81940.0 in 2022, then surged by 78.74% to $146456.0 in 2023, then rose by 23.73% to $181203.0 in 2024, then decreased by 3.98% to $174000.0 in 2025, then plummeted by 88.51% to $20000.0 in 2026.
  • According to Business Quant data, Gross Profit over the past three periods came in at $20000.0, $174000.0, and $174000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.